VivoSeq
Metabolic & Endocrine

Type 2 Diabetes

715

Pipeline Programs↗

182

Active Trials↗

155

Companies Involved↗

Type 2 Diabetes is a highly competitive landscape with 715 programs across 155 companies. The most active players are Halozyme Therapeutics, Theracos, Daewoong Pharmaceutical Co. LTD.. 190 therapies are approved with 160 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

100/100

Pipeline Velocity

82/100

Mech. Concentration

6/100

Completion Rate

91/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

Halozyme Therapeutics

2 programs

Phase 1Theracos logo

Theracos

1 program

Phase 1Daewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.

1 program

Phase 1A

Akros Pharma Inc.

1 program

Phase 1G

Gan and Lee Pharmaceuticals, USA

1 program

Phase 1C

Catabasis Pharmaceuticals

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical79

Glargine

Eli Lilly

Insulins Human

Eli Lilly

Iloprost

BTG International Inc.

Esomeprazole

Dexcel Pharma Technologies Ltd.

Propranolol

Wyeth-Lederle Vaccines

Phase 1101

LY3814645

Eli Lilly

Losartan

Organon and Co

Caffeine

Hikma Pharmaceuticals LLC

Efavirenz

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Thyroid Hormone

Merck & Co.

Phase 2185

Cagrilintide

Novo Nordisk

LY2510924

Eli Lilly

Calcium Carbonate

Otsuka

Celecoxib

Philadelphia Eye Associates

Colesevelam

Cosette Pharmaceuticals, Inc.

Phase 3160

Orforglipron

Eli Lilly

Retatrutide

Eli Lilly

Bexagliflozin

Theracosbio

Pantoprazole

Wyeth-Lederle Vaccines

Valsartan

Novartis

Approved190

Tirzepatide

Eli Lilly

Dapagliflozin

AstraZeneca

Finerenone

Bayer

Ropivacaine

Fresenius Kabi Oncology Ltd.

Semaglutide

Novo Nordisk

Analysis

Modality Breakdown

95%

Small molecule

814 of 855 classified programs — the dominant modality here.

5%ALL OTHERSPeptide324%Monoclonal antibody5<1%Cell therapy3<1%Protein / enzyme1<1%

Small molecule leads; the ring shows all 855 classified programs, each share of the total. Modality classified for 98% of 886 pipeline programs.

Analysis

Trial Status

1,791

clinical trials

Completed1,343 · 75%
Unknown status127 · 7%
Terminated97 · 5%
Recruiting79 · 4%
Not yet recruiting52 · 3%
Active, not recruiting45 · 3%
Other48 · 3%

Clinical Trials

Trial Activity

1791 trials

The Effect of Gliatamin (Chonline Alphoscerate) on Depressive Mood in Type 2 Diabetes Patients
Recruiting·YYonsei University·Phase 4·NCT03059069·60 enrolled
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
Recruiting·UUniversity of Washington·Phase 4·NCT05780905·50 enrolled
Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)
Recruiting·—·N/A·NCT07359105·2,186 enrolled
Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction
Recruiting·MMedical College of Wisconsin·Phase 1·NCT05593549·60 enrolled
Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)
Recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 4·NCT03087032·164 enrolled
Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes
Recruiting·Chong Kun Dang Pharmaceutical logoChong Kun Dang Pharmaceutical·N/A·NCT06838286·10,000 enrolled
SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary
Recruiting·Novo Nordisk logoNovo Nordisk·N/A·NCT06269120·470 enrolled
Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes
Recruiting·GGT Metabolic Solutions, Inc.·N/A·NCT07317115·20 enrolled
Para-Probiotic Oral Care in Periodontal Patients With Type 2 Diabetes
Recruiting·UUniversity of Pavia·N/A·NCT07069166·40 enrolled
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes
Recruiting·AAmsterdam UMC, location VUmc·Phase 4·NCT06983054·34 enrolled
A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH)
Recruiting·—·N/A·NCT06627322·5,950 enrolled
Efficacy and Safety of Henagliflozin Proline and Metformin Hydrochloride Extended-release Tablets (Ⅰ) Versus Metformin Tablets in Patients With New-onset Type 2 Diabetes: a Multicenter, Randomized Controlled Study
Recruiting·ZZhejiang Provincial People's Hospital·Phase 4·NCT06888050·268 enrolled
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
Recruiting·—·Phase 4·NCT05390892·6,000 enrolled
Impact of P53 and SIRT1 in Type 2 Diabetes
Recruiting·—·Phase 3·NCT03925714·90 enrolled
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
Recruiting·Eli Lilly logoEli Lilly·Phase 1·NCT06945419·201 enrolled
Page 1 of 120

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)